POLBF / Poolbeg Pharma up 8% on deal with Nasdaq biotech

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) said the potential of its lead asset will be discussed at a leading medical conference in December. A poste more_horizontal

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) is hosting an investor and analyst meeting focusing on its POLB 001 Oncology Programme, targeting cytokin more_horizontal

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) said it has secured an endorsement from its scientific advisory board (SAB) of the prioritised targets for more_horizontal

Shares in Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) rose 8% in early trading after the company announced a partnership with an unnamed Nasdaq-listed more_horizontal

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) said it has inked an agreement with an unnamed Nasdaq-listed biopharmaceutical entity aimed at developing more_horizontal

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF), the clinical-stage biopharmaceutical group, has announced the cancellation of the European Patent Office ( more_horizontal

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF), the clinical-stage biopharmaceutical firm, recently received a notice of allowance from the Japanese Paten more_horizontal

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) said that an unnamed 'third party' has agreed to withdraw its opposition to one of the company's European more_horizontal